CINECA IRIS Institutional Research Information System

BRINGHEN, Sara
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 4.878
EU - Europa 3.189
AS - Asia 1.604
SA - Sud America 143
OC - Oceania 74
AF - Africa 48
Continente sconosciuto - Info sul continente non disponibili 1
Totale 9.937
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.661
IT - Italia 1.049
CN - Cina 684
JP - Giappone 377
SE - Svezia 356
IE - Irlanda 281
FR - Francia 253
GB - Regno Unito 249
DE - Germania 200
CA - Canada 169
IN - India 161
ES - Italia 145
VN - Vietnam 94
NL - Olanda 89
UA - Ucraina 85
AT - Austria 81
KR - Corea 66
AU - Australia 63
PL - Polonia 61
FI - Finlandia 58
BE - Belgio 57
CH - Svizzera 57
BR - Brasile 49
TR - Turchia 42
MX - Messico 35
GR - Grecia 33
SG - Singapore 33
CO - Colombia 30
HK - Hong Kong 28
HU - Ungheria 26
PE - Perù 23
IL - Israele 21
PT - Portogallo 18
AR - Argentina 17
TW - Taiwan 17
NO - Norvegia 15
SN - Senegal 15
DK - Danimarca 14
RU - Federazione Russa 14
TH - Thailandia 13
UY - Uruguay 12
MY - Malesia 11
HR - Croazia 10
NZ - Nuova Zelanda 10
PK - Pakistan 10
RO - Romania 8
TN - Tunisia 8
NG - Nigeria 7
ID - Indonesia 6
KW - Kuwait 6
SA - Arabia Saudita 6
TT - Trinidad e Tobago 6
CL - Cile 5
QA - Qatar 5
AE - Emirati Arabi Uniti 4
AM - Armenia 4
CZ - Repubblica Ceca 4
EC - Ecuador 4
EG - Egitto 4
MA - Marocco 4
MT - Malta 4
UZ - Uzbekistan 4
AD - Andorra 3
BG - Bulgaria 3
DZ - Algeria 3
IR - Iran 3
JO - Giordania 3
KE - Kenya 3
MK - Macedonia 3
PH - Filippine 3
SI - Slovenia 3
KY - Cayman, isole 2
LU - Lussemburgo 2
MD - Moldavia 2
RS - Serbia 2
SK - Slovacchia (Repubblica Slovacca) 2
VE - Venezuela 2
ZA - Sudafrica 2
BD - Bangladesh 1
CR - Costa Rica 1
CU - Cuba 1
EE - Estonia 1
ET - Etiopia 1
EU - Europa 1
GH - Ghana 1
GL - Groenlandia 1
IS - Islanda 1
JM - Giamaica 1
NP - Nepal 1
PA - Panama 1
PF - Polinesia Francese 1
PY - Paraguay 1
TJ - Tagikistan 1
Totale 9.937
Salva come PNG Salva come JPEG
Città #
Fairfield 383
Chandler 317
Dublin 272
Redwood City 263
Torino 227
Beijing 221
Cambridge 186
Florence 181
Ashburn 162
Houston 161
Woodbridge 153
Wilmington 135
Ann Arbor 126
Nyköping 123
Seattle 119
Tokyo 115
Turin 95
Dearborn 84
Ottawa 77
Vienna 73
Medford 72
Princeton 70
Duncan 60
Pisa 60
London 53
Villeurbanne 53
Dong Ket 46
Shanghai 45
Hangzhou 42
New York 38
Boston 37
Brussels 37
Jacksonville 36
Nanjing 35
Raritan 35
Rochester 35
Warsaw 34
Guangzhou 33
Portland 33
San Diego 32
Paris 30
Los Angeles 29
Norwalk 29
Newbury Park 26
Seoul 26
Toronto 26
Madrid 25
Chicago 23
Chengdu 22
Barcelona 21
Minneapolis 20
San Mateo 20
Sydney 20
Hebei 19
Lima 19
Rome 19
Baltimore 18
Brzeg 18
Flushing 17
Hyderabad 17
Milan 17
San Francisco 17
Durham 16
Xian 16
Budapest 15
Phoenix 15
Providence 15
Singapore 15
Wuhan 15
Athens 14
Changchun 14
Pittsburgh 14
Atlanta 13
Campi Bisenzio 13
Changsha 13
Scarsdale 13
São Paulo 13
Boardman 12
Charlotte 12
Grand Rapids 12
Montevideo 12
Toledo 12
Central District 11
Greenville 11
Honolulu 11
Mumbai 11
Omaha 11
Philadelphia 11
Sanayi 11
St Louis 11
Breda 10
Chennai 10
Columbus 10
Dallas 10
Fremont 10
Fukuoka 10
Indianapolis 10
Jinan 10
Osaka 10
Pune 10
Totale 5.299
Salva come PNG Salva come JPEG
Nome #
Once-weekly carfilzomib, pomalidomide, and low-dose dexamethasone for relapsed/refractory myeloma: a phase I/II study 1.879
Patient-centered practice in elderly myeloma patients: an overview and consensus from the European Myeloma Network (EMN) 838
A phase 2 study of three low-dose intensity subcutaneous bortezomib regimens in elderly frail patients with untreated multiple myeloma 740
Triplet vs doublet lenalidomide-containing regimens for the treatment of elderly patients with newly diagnosed multiple myeloma 496
Prevention, monitoring and treatment of cardiovascular adverse events in myeloma patients receiving carfilzomib A consensus paper by the European Myeloma Network and the Italian Society of Arterial Hypertension 361
Pomalidomide, cyclophosphamide, and prednisone for relapsed/refractory multiple myeloma: a multicenter phase 1/2 open-label study. 301
Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group 293
Clinical and pharmacologic features of monoclonal antibodies and checkpoint blockade therapy in multiple myeloma 263
European Myeloma Network Guidelines for the Management of Multiple Myeloma-related Complications 248
Impact of New Drugs on the Long-Term Follow-Up of Upfront Tandem Autograft-Allograft in Multiple Myeloma 244
Lenalidomide and low-dose dexamethasone (Rd) versus bortezomib, melphalan, prednisone (VMP) in elderly newly diagnosed multiple myeloma patients: A comparison of two prospective trials 214
Early mortality in myeloma patients treated with first-generation novel agents thalidomide, lenalidomide, bortezomib at diagnosis: A pooled analysis 189
Predicting poor peripheral blood stem cell collection in patients with multiple myeloma receiving pre-transplant induction therapy with novel agents and mobilized with cyclophosphamide plus granulocyte-colony stimulating factor: Results from a Gruppo Italiano Malattie EMatologiche dell'Adulto Multiple Myeloma Working Party study 182
Pharmacokinetic evaluation of pomalidomide for the treatment of myeloma 178
Salvage therapy in first relapse: a retrospective study in a large patient population with multiple myeloma 174
Determining treatment intensity in elderly patients with multiple myeloma 166
Treatment of newly diagnosed elderly multiple myeloma 165
How is patient care for multiple myeloma advancing? 164
Phase 1/2 study of weekly carfilzomib, cyclophosphamide, dexamethasone in newly diagnosed transplant-ineligible myeloma 153
Emerging drugs and combinations to treat multiple myeloma 139
Does low-molecular-weight heparin influence the antimyeloma effects of thalidomide? A retrospective analysis of data from the GIMEMA, nordic and turkish myeloma study groups 131
Lenalidomide maintenance after autologous stem-cell transplantation in newly diagnosed multiple myeloma: A meta-analysis 129
Carfilzomib, cyclophosphamide and dexamethasone for newly diagnosed, high-risk myeloma patients not eligible for transplant: a pooled analysis of two studies 125
Lenalidomide-based induction and maintenance in elderly newly diagnosed multiple myeloma patients: updated results of the EMN01 randomized trial 123
A Simple Score, Based On Geriatric Assessment, Improves Prediction of Survival, and Risk Of Serious Adverse Events In Elderly Newly Diagnosed Multiple Myeloma Patients 121
Prognostic or predictive value of circulating cytokines and angiogenic factors for initial treatment of multiple myeloma in the GIMEMA MM0305 randomized controlled trial 107
Geriatric assessment predicts survival and toxicities in elderly myeloma patients: An International Myeloma Working Group report 104
Early Relapse Risk in Patients with Newly Diagnosed Multiple Myeloma Characterized by Next-generation Sequencing 104
Cardiovascular adverse events in modern myeloma therapy - Incidence and risks. A review from the European Myeloma Network (EMN) and Italian Society of Arterial Hypertension (SIIA) 103
Dose/schedule-adjusted Rd-R vs continuous Rd for elderly, intermediate-fit patients with newly diagnosed multiple myeloma 95
Once-weekly versus twice-weekly carfilzomib in patients with newly diagnosed multiple myeloma: A pooled analysis of two phase i/ii studies 89
First-line therapy with either bortezomib-melphalan-prednisone or lenalidomide-dexamethasone followed by lenalidomide for transplant-ineligible multiple myeloma patients: a pooled analysis of two randomized trials 88
A longitudinal analysis of chromosomal abnormalities in disease progression from MGUS/SMM to newly diagnosed and relapsed multiple myeloma 85
Current Phase II investigational proteasome inhibitors for the treatment of multiple myeloma 81
Recommendations for vaccination in multiple myeloma: a consensus of the European Myeloma Network 81
Age and organ damage correlate with poor survival in myeloma patients: meta-analysis of 1435 individual patient data from 4 randomized trials 79
Treatment of newly diagnosed elderly multiple myeloma 73
Effects of Carfilzomib Therapy on Left Ventricular Function in Multiple Myeloma Patients 67
Octogenarian newly diagnosed multiple myeloma patients without geriatric impairments: the role of age >80 in the IMWG frailty score 67
Monoclonal antibodies to treat multiple myeloma: A dream come true 67
Maintenance Treatment and Survival in Patients With Myeloma A Systematic Review and Network Meta-analysis 66
Bortezomib, melphalan, prednisone (VMP) versus melphalan, prednisone, thalidomide (MPT) in elderly newly diagnosed multiple myeloma patients: A retrospective case-matched study. 65
Systemic virotherapy for multiple myeloma 54
Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: updated follow-up and improved survival. 52
Efficacy and safety of once-weekly bortezomib in multiple myeloma patients. 50
Melphalan and its role in the management of patients with multiple myeloma 49
Multiple myeloma patients undergoing carfilzomib: Development and validation of a risk score for cardiovascular adverse events prediction 48
Melphalan, prednisone, and thalidomide versus thalidomide, dexamethasone, and pegylated liposomal doxorubicin regimen in very elderly patients with multiple myeloma: a case-match study. 46
Lenalidomide-prednisone induction followed by lenalidomide-melphalan-prednisone consolidation and lenalidomide-prednisone maintenance in newly diagnosed elderly unfit myeloma patients. 46
Lenalidomide and low-dose dexamethasone for newly diagnosed primary plasma cell leukemia. 46
Monoclonal antibodies currently in Phase II and III trials for multiple myeloma 46
Safety of Rapid Daratumumab Infusion: A Retrospective, Multicenter, Real-Life Analysis on 134 Patients With Multiple Myeloma 46
Evaluation of Cardiovascular Toxicity Associated with Treatments Containing Proteasome Inhibitors in Multiple Myeloma Therapy 45
Ultra-Low-Dose Whole-Body Computed Tomography Protocol Optimization for Patients With Plasma Cell Disorders: Diagnostic Accuracy and Effective Dose Analysis From a Reference Center 45
Ixazomib-based induction regimens plus ixazomib maintenance in transplant-ineligible, newly diagnosed multiple myeloma: the phase II, multi-arm, randomized UNITO-EMN10 trial 44
Bortezomib, melphalan, and prednisone in elderly relapsed/refractory multiple myeloma patients: update of multicenter, open-label Phase 1/2 study 41
New treatment strategies for elderly myeloma patients 41
Cost efficiency and effectiveness of biosimilar filgrastim in autologous transplant 41
Approach to the Older Adult With Multiple Myeloma 38
The role of monoclonal antibodies in the first-line treatment of transplant-ineligible patients with newly diagnosed multiple myeloma 38
Melflufen: A Peptide-Drug Conjugate for the Treatment of Multiple Myeloma 33
A longitudinal analysis of chromosomal abnormalities in disease progression from MGUS/SMM to newly diagnosed and relapsed multiple myeloma 21
The prevalence and outcomes of frail older adults in clinical trials in multiple myeloma: A systematic review 2
Totale 10.309
Salva come PNG Salva come JPEG
Categoria #
all - tutte 17.381
article - articoli 0
book - libri 0
conference - conferenze 383
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 17.764
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/2019563 0 0 28 57 57 24 30 67 47 63 120 70
2019/20201.156 49 30 44 135 89 123 111 100 203 99 97 76
2020/20212.274 74 134 164 146 205 220 195 201 230 198 201 306
2021/20222.425 174 173 148 238 176 139 268 141 127 199 295 347
2022/20232.548 149 199 178 202 178 329 198 231 267 171 247 199
2023/2024572 180 243 149 0 0 0 0 0 0 0 0 0
Totale 10.309